Halozyme Reports Fourth Quarter And Full-Year 2018 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Halozyme Therapeutics (HALO) Tops Q4 EPS by 2c, FY Guidance Beats
February 21, 2019 4:06 PM ESTHalozyme Therapeutics (NASDAQ: HALO) reported Q4 EPS of ($0.01), $0.02 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $60.2 million versus the consensus estimate of $59.77 million.
GUIDANCE:
Halozyme Therapeutics sees FY2019 revenue of $205-215 million, versus the consensus of... More
